The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody.
about
Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccinationImmune signaling by RIG-I-like receptorsMDA5-positive dermatomyositis: an uncommon entity in Europe with variable clinical presentationsRecent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory MyopathiesLupus pathobiology based on genomics.MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis.Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositisMyositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis.Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.Meta-analysis of the association of dermatomyositis and polymyositis with cancer.Amyopathic dermatomyositis: definitions, diagnosis, and management.Novel autoantibodies and clinical phenotypes in adult and juvenile myositis.Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosisPrognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control studyThe mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective studyMyositis-specific autoantibodies: detection and clinical associations.Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma.The lung as a possible target for the immune reaction in myositis.Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan.Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies.Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-AnalysisHMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease.Autoantibodies to transcription intermediary factor TIF1β associated with dermatomyositis.PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome.Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weaknessAnti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum.Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents.A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature.IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis/dermatomyositisClinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.Myositis autoantibodies.Autoantibodies in polymyositis and dermatomyositis.Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis.Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysisAutoimmunity versus autoinflammation--friend or foe?The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis.
P2860
Q21131298-35467BD3-7C8F-4233-81AE-0AB3F873D6A9Q24304438-71873C38-014A-4F76-94A3-1048525A5334Q26777975-B90AF30A-FBDE-4FD9-937E-F74CE3351D8BQ26798023-E7701A5F-D616-4BF5-A3E7-DE11614C18C9Q33364409-3075ADC7-8B84-4A95-B5F6-EA65B4718673Q33592767-08F3FA82-D6D8-404E-AF95-CBAE7AB04DB4Q33688739-A589DE38-EC8B-4C03-86E8-E888A2C5C4A0Q33704562-73B6FC65-1626-4837-A80C-7B1966D66043Q33814323-25490482-A7E6-4891-9C21-F7F983189F3CQ34486301-CDEDB959-6A7B-451E-9300-CB913248FDC1Q34654935-131F257C-CC95-4AE2-9567-CC0E5084B9A5Q34666022-C8046B1D-3E85-4AED-A1D8-3D8F4CD5C97FQ35092898-5D27B453-50A3-4B62-B0EB-A1A4328BFCDEQ35163334-1B08660B-9A38-4263-B72C-9C11AAE0DE61Q35195954-AFFB5154-28D1-4FD3-80BC-EF254CDF10BBQ35198594-74A47C50-4F51-4F8E-ABD1-B55570CBD998Q35309808-D31433C5-A582-4968-AF04-87B3F6A4DF1CQ35532333-5389750D-78E8-438E-9E78-8745C94C622FQ35617570-E123CB6A-314D-4D04-886C-7A0DC0BAE200Q35864644-77D85F19-D34B-49D6-8B49-482085D20C66Q35907850-614303BC-1256-423B-8F48-3855306AD0A7Q35999311-BAE302DF-1703-4956-BF1F-D702DB3FD17FQ36015534-95CAD0AF-5C66-4CE6-9983-F071BA7BE604Q36106996-34448747-D1EF-45CC-8407-D36B1589DE9EQ36245820-F6821C06-BFDB-48D9-B95C-B5F7E9517C3EQ36788809-C396C688-AB55-486E-9D12-4A77B0CC73B7Q36903076-D1D65F07-8C42-4D3F-9A25-EF5A1F3BEB5FQ36926351-2D7C4CBF-4838-4672-AD61-C74A7A2509AEQ36947409-D2E6C759-88C3-4566-8BAE-659F7F204F4EQ36994516-EE3CBDAE-0486-4F0E-9C22-C2CC93E71280Q37053219-63FC907D-E351-4EC4-906D-1BF2A5431EB6Q37706152-0FB0EC43-3522-44D5-BBD4-CD769BF2CC68Q37938701-CB5AB2D9-F91F-4EDE-9DEF-AFA7712B6049Q37988393-4B478490-35AD-47A8-8518-633E4FF0B763Q38041385-F6CEA730-E052-4E28-B8CF-BE6323514AFFQ38099556-12CD96D0-AF3A-48FC-99C3-70ACE94506F0Q38124282-E73C730F-CCA8-451B-9F80-CE7E398DE0A6Q38125957-B21F1039-45E8-4B9F-871F-751D55A017EEQ38227340-269264CB-32CF-446E-B2E5-0DAB1252ADE3Q38258248-25F5D454-53B7-4734-8F33-6A54431A1F61
P2860
The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
The RIG-I-like receptor IFIH1/ ...... by the anti-CADM-140 antibody.
@en
The RIG-I-like receptor IFIH1/ ...... by the anti-CADM-140 antibody.
@nl
type
label
The RIG-I-like receptor IFIH1/ ...... by the anti-CADM-140 antibody.
@en
The RIG-I-like receptor IFIH1/ ...... by the anti-CADM-140 antibody.
@nl
prefLabel
The RIG-I-like receptor IFIH1/ ...... by the anti-CADM-140 antibody.
@en
The RIG-I-like receptor IFIH1/ ...... by the anti-CADM-140 antibody.
@nl
P2093
P2860
P356
P1433
P1476
The RIG-I-like receptor IFIH1/ ...... by the anti-CADM-140 antibody.
@en
P2093
Daisuke Kawabata
Hajime Yoshifuji
Katsuya Okawa
Koichiro Ohmura
Naoichiro Yukawa
Ran Nakashima
Shio Kobayashi
Takaki Nojima
Takao Fujii
Takashi Usui
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEP375
P577
2009-12-16T00:00:00Z